References

Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life

10.1002/ana.10712 · ExternalCitation · doi-reference

GABAergic disinhibition and impaired KCC2 cotransporter activity underlie tumor-associated epilepsy

10.1002/glia.22730 · ExternalCitation · doi-reference

Extra-temporal pediatric low-grade gliomas and epilepsy

10.1007/s00381-024-06573-8 · ExternalCitation · doi-reference

Neuronal activity promotes glioma growth through neuroligin-3 secretion

10.1016/j.cell.2015.04.012 · ExternalCitation · doi-reference

The IDH1 inhibitor ivosidenib improved seizures in a patient with drug-resistant epilepsy from IDH1 mutant oligodendroglioma

10.1016/j.ebr.2022.100526 · ExternalCitation · doi-reference

Compromised GABAergic inhibition contributes to tumor-associated epilepsy

10.1016/j.eplepsyres.2016.07.010 · ExternalCitation · doi-reference

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

10.1016/s0140-6736(12)61134-9 · ExternalCitation · doi-reference

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

10.1016/s0140-6736(16)31419-2 · ExternalCitation · doi-reference

Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial

10.1016/s1470-2045(21)00578-7 · ExternalCitation · doi-reference

Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial

10.1016/s1470-2045(25)00472-3 · ExternalCitation · doi-reference

Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management

10.1016/s1474-4422(07)70103-5 · ExternalCitation · doi-reference

The complexities underlying epilepsy in people with glioblastoma

10.1016/s1474-4422(23)00031-5 · ExternalCitation · doi-reference

Glutamate release by primary brain tumors induces epileptic activity

10.1038/nm.2453 · ExternalCitation · doi-reference

Seizures and gliomas – towards a single therapeutic approach

10.1038/nrneurol.2016.26 · ExternalCitation · doi-reference

Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate

10.1038/s41467-018-03905-6 · ExternalCitation · doi-reference

IDH inhibition in gliomas: from preclinical models to clinical trials

10.1038/s41582-024-00967-7 · ExternalCitation · doi-reference

Electrical and synaptic integration of glioma into neural circuits

10.1038/s41586-019-1563-y · ExternalCitation · doi-reference

Glutamatergic synaptic input to glioma cells drives brain tumour progression

10.1038/s41586-019-1564-x · ExternalCitation · doi-reference

Glioblastoma remodelling of human neural circuits decreases survival

10.1038/s41586-023-06036-1 · ExternalCitation · doi-reference

BRAF somatic mutation contributes to intrinsic epileptogenicity in pediatric brain tumors

10.1038/s41591-018-0172-x · ExternalCitation · doi-reference

Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations

10.1056/nejmoa2303815 · ExternalCitation · doi-reference

Vorasidenib in IDH1- or IDH2-mutant low-grade glioma

10.1056/nejmoa2304194 · ExternalCitation · doi-reference

SNO and EANO practice guideline update: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors

10.1093/neuonc/noab152 · ExternalCitation · doi-reference

INNV-20. Radiographic response and seizure control in IDH1 mutant glioma patients using ivosidenib

10.1093/neuonc/noab196.431 · ExternalCitation · doi-reference

Heterogeneity and excitability of BRAFV600E-induced tumors is determined by Akt/mTOR-signaling state and Trp53-loss

10.1093/neuonc/noab268 · ExternalCitation · doi-reference

IDH-mutated gliomas promote epileptogenesis through d-2-hydroxyglutarate-dependent mTOR hyperactivation

10.1093/neuonc/noac003 · ExternalCitation · doi-reference

EANO – EURACAN – SNO Guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors

10.1093/neuonc/noac188 · ExternalCitation · doi-reference

IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas

10.1093/neuonc/noac197 · ExternalCitation · doi-reference

Brain tumor-related epilepsy management: a Society for Neuro-Oncology (SNO) consensus review on current management

10.1093/neuonc/noad154 · ExternalCitation · doi-reference

The excitatory milieu in glioma: mechanisms and therapeutic avenues

10.1093/neuonc/noaf063 · ExternalCitation · doi-reference

Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials

10.1093/neuonc/now190 · ExternalCitation · doi-reference

Epilepsy in gliomas: recent insights into risk factors and molecular pathways

10.1097/wco.0000000000001214 · ExternalCitation · doi-reference

Multiomics technologies and molecular biomarkers in brain tumor-related epilepsy

10.1111/cns.14717 · ExternalCitation · doi-reference

Early seizure freedom with [18F]fluorodopa positron emission tomography response after isocitrate dehydrogenase inhibition with vorasidenib: first case report

10.1111/epi.18593 · ExternalCitation · doi-reference

SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma

10.1126/scitranslmed.aaa8103 · ExternalCitation · doi-reference

Impact of frontline ivosidenib on volumetric growth patterns in isocitrate dehydrogenase–mutant astrocytic and oligodendroglial tumors

10.1158/1078-0432.ccr-23-0585 · ExternalCitation · doi-reference

Pilot trial of perampanel on peritumoral hyperexcitability in newly diagnosed high-grade glioma

10.1158/1078-0432.ccr-24-1849 · ExternalCitation · doi-reference

FDA approval summary: tovorafenib for relapsed or refractory BRAF-altered pediatric low-grade glioma

10.1158/1078-0432.ccr-24-3439 · ExternalCitation · doi-reference

FDA approval summary: vorasidenib for IDH-mutant grade 2 astrocytoma or oligodendroglioma following surgery

10.1158/1078-0432.ccr-25-1333 · ExternalCitation · doi-reference

Postoperative risk of IDH-mutant glioma-associated seizures and their potential management with IDH-mutant inhibitors

10.1172/jci168035 · ExternalCitation · doi-reference

Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial

10.1186/s13063-021-05977-0 · ExternalCitation · doi-reference

BRAF inhibition in BRAF(V600)-mutant gliomas: results from the VE-BASKET Study

10.1200/jco.2018.78.9990 · ExternalCitation · doi-reference

Can targeting TSP-1 with gabapentin enhance survival in glioblastoma? A 20-year retrospective cohort study

10.1200/jco.2024.42.16_suppl.2048 · ExternalCitation · doi-reference

A randomized, double-blind, phase 3 study of vorasidenib versus placebo in patients with mutant IDH1/2 diffuse glioma (INDIGO): analysis of health-related quality of life, neurocognition and seizures (PL5.003)

10.1212/wnl-.0000000000205578 · ExternalCitation · doi-reference

Mutant IDH1 and seizures in patients with glioma

10.1212/wnl.0000000000003911 · ExternalCitation · doi-reference

Tissue 2-hydroxyglutarate and preoperative seizures in patients with diffuse gliomas

10.1212/wnl.0000000000012893 · ExternalCitation · doi-reference

Association of clinical, tumor, and treatment characteristics with seizure control in patients with IDH1/2-mutant lower-grade glioma

10.1212/wnl.0000000000209352 · ExternalCitation · doi-reference

Efficacy of clobazam as an add-on therapy in brain tumor-related epilepsy

10.1212/wnl.94.15_supplement.2687 · ExternalCitation · doi-reference

Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study

10.1371/journal.pone.0158476 · ExternalCitation · doi-reference

AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro

10.1371/journal.pone.0211644 · ExternalCitation · doi-reference

Sulfasalazine for brain cancer fits

10.1517/13543784.2012.670634 · ExternalCitation · doi-reference

Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, IDH1-mutant glioblastoma: a case report from a phase I study

10.2217/cns-2020-0014 · ExternalCitation · doi-reference

Perampanel confirms to be effective and well tolerated as an add-on treatment in patients with brain tumor-related epilepsy (PERADET study)

10.3389/fneur.2020.00592 · ExternalCitation · doi-reference

Sulfasalazine and temozolomide with radiation therapy for newly diagnosed glioblastoma

10.4103/0028-3886.128280 · ExternalCitation · doi-reference